Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared on X:
“Does the timing of anti-PD-1 infusions matter? (NCI/SWOG S1404, n=628).
Tite: Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy
Authors: Megan Othus, Thach-Giao Truong, Elad Sharon, Kari Kendra, Kenneth Grossmann, Elizabeth Buchbinder, Nikhil I. Khushalani, Zeynep Eroglu, Sunandana Chandra, Gary C. Doolittle, John M. Kirkwood, Alexandra Ikeguchi, Catalin Mihalcioiu, C. Lance Cowey, Sunil A. Reddy, Douglas B. Johnson, Matthew Taylor, Vernon K. Sondak, Antoni Ribas, Sapna P. Patel
Read The Full Article
No association between earlier infusion time and RFS or OS after bias-adjusted analyses
Time-dependent multivariable models failed to confirm any survival benefit
Distance to the treatment center influenced infusion timing, highlighting an important confounder
Maybe the clock wasn’t ticking in favor of IO…just in favor of bias!”
